1. Home
  2. |Insights
  3. |Fundamental Shift in GSA Schedule Contract Pricing?

Fundamental Shift in GSA Schedule Contract Pricing?

Client Alert | 1 min read | 10.08.08

The Multiple Award Schedule ("MAS") Advisory Panel, established in March 2008 to review pricing and price reduction provisions of the MAS program, has voted to recommend that GSA eliminate, on a gradual basis, the Price Reduction Clause for purchases of both products and services under the Schedule and adopt different and better mechanisms to achieve pricing transparency and competition at both the Schedule contract level and task/delivery order level. The Panel will present its recommendations to the GSA Administrator later this year.

-----------------------

Crowell & Moring Government Contracts Group is pleased to announce a second bullet point service that will focus exclusively on GSA Schedule contracting. GSA Schedule contracts have unique requirements, risks, and rewards, and the products and services purchased by federal and state governments through this contracting vehicle are expanding in scope and volume.

The GSA Schedule Bullet Points will alert you to:

  • changes in the law and policy affecting GSA Schedule contracts
  • new case law affecting GSA Schedule contracts
  • seminars and publications offered by Crowell & Moring of interest to GSA Schedule contract holders

Please respond to this email if you would like to be included in this new bullet point service. Feel free to forward this invitation to others who might be interested in receiving our GSA Schedule Bullet Points.

Insights

Client Alert | 4 min read | 08.29.25

Gender-Affirming Care Targeted for Potential False Claims Act Enforcement

On August 19, 2025, the Office of Personnel Management (OPM) informed insurers participating in the Federal Employees Health Benefits or Postal Service Health Benefits programs that gender-affirming care would no longer be covered for federal workers starting in 2026. This coverage decision is the Trump Administration’s latest action stemming from Executive Order 14187 which aims to prevent certain treatments, such as gender-affirming hormone therapy, surgeries, and puberty blockers for those under the age of 19. As previously discussed, the Administration has also signaled its intent to use various law enforcement tools against gender-affirming care, including  Section 5 of the Federal Trade Commission Act to police false or unsupported claims by medical professionals about gender-affirming treatments....